XML 86 R65.htm IDEA: XBRL DOCUMENT v2.4.1.9
DIVESTITURES (Details) (USD $)
In Millions, unless otherwise specified
0 Months Ended 1 Months Ended 3 Months Ended 1 Months Ended 0 Months Ended 3 Months Ended 1 Months Ended
Jul. 01, 2014
Oct. 31, 2013
Dec. 31, 2013
Feb. 29, 2012
Jul. 10, 2014
Sep. 30, 2014
Jul. 31, 2014
Dec. 31, 2014
Asset acquisitions and disposition                
Milestone payments     $ 0vrx_CollaborativeAgreementMilestonePaymentsDue         $ 62.0vrx_CollaborativeAgreementMilestonePaymentsDue
Period of payment of minimum royalties from commercialization of development product 3 years              
Skincare Products                
Asset acquisitions and disposition                
Net cash proceeds   13.7us-gaap_ProceedsFromDivestitureOfBusinesses
/ us-gaap_SignificantAcquisitionsAndDisposalsByTransactionAxis
= vrx_DiscontinuedOTCSkincareMember
13.7us-gaap_ProceedsFromDivestitureOfBusinesses
/ us-gaap_SignificantAcquisitionsAndDisposalsByTransactionAxis
= vrx_DiscontinuedOTCSkincareMember
         
Gain (loss) on sale of business     (10.2)us-gaap_GainLossOnSaleOfBusiness
/ us-gaap_SignificantAcquisitionsAndDisposalsByTransactionAxis
= vrx_DiscontinuedOTCSkincareMember
         
Potential additional earn-out payments, period   12 months            
Clindamycin and benzoyl peroxide gel ("IDP-111") and Fluorouracil cream ("5-FU")                
Asset acquisitions and disposition                
Net cash proceeds       66.3us-gaap_ProceedsFromDivestitureOfBusinesses
/ us-gaap_SignificantAcquisitionsAndDisposalsByTransactionAxis
= vrx_ClindamycinAndBenzoylPeroxideGelAndFluorouracilCreamMember
       
Filler and Toxin Group                
Asset acquisitions and disposition                
Net cash proceeds         1,400.0us-gaap_ProceedsFromDivestitureOfBusinesses
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= vrx_FillerandToxinGroupMember
     
Gain (loss) on sale of business           323.9us-gaap_GainLossOnSaleOfBusiness
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= vrx_FillerandToxinGroupMember
   
Disposal group, costs to sell for divestiture           43vrx_DisposalGroupNotDiscontinuedOperationTransactionCosts
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= vrx_FillerandToxinGroupMember
   
Metronidazole 1.3 Percent Vaginal Gel Antibiotic Development Product [Member]                
Asset acquisitions and disposition                
Gain (loss) on sale of business           (58.5)us-gaap_GainLossOnSaleOfBusiness
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= vrx_Metronidazole1.3PercentVaginalGelAntibioticDevelopmentProductMember
   
Milestone payments 10.0vrx_CollaborativeAgreementMilestonePaymentsDue
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= vrx_Metronidazole1.3PercentVaginalGelAntibioticDevelopmentProductMember
             
PreCision Tretin-X Cream Product                
Asset acquisitions and disposition                
Up-front purchase price             70vrx_DivestitureUpfrontPurchasePrice
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= vrx_PreCisionTretinXCreamProductMember
 
Precision Generic Tretinoin Products                
Asset acquisitions and disposition                
Gain (loss) on sale of business           (8.8)us-gaap_GainLossOnSaleOfBusiness
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= vrx_PrecisionGenericTretinoinProductsMember
   
Up-front purchase price             $ 45vrx_DivestitureUpfrontPurchasePrice
/ us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis
= vrx_PrecisionGenericTretinoinProductsMember